Myocardial Work Brings New Insights into Left Ventricular Remodelling in Cardio-Oncology Patients

• Autor(a) principal: Vaz Ferreira, V
• Data de Publicação: 2022
• Outros Autores: Mano, T, Cardoso, I, Coutinho Cruz, M, Branco, LM, Almeida-Morais, L, Timóteo, AT, Galrinho, A, Castelo, A, Garcia Brás, P, Simão, D, Sardinha, M, Gonçalves, A, Cruz Ferreira, R
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.17/4010
• topic: HSM CAR; HSAC ONC; Breast Neoplasms* / complications; Humans; Female; Middle Aged; Breast Neoplasms* / drug therapy; Heart Diseases*; Stroke Volume; Ventricular Dysfunction, Left* / chemically induced; Ventricular Dysfunction, Left* / chemically induced; Ventricular Dysfunction, Left* / diagnostic imaging; Ventricular Function, Left; Ventricular Remodeling

Serial transthoracic echocardiographic (TTE) assessment of 2D left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) are the gold standard screening methods for cancer therapeutics-related cardiac dysfunction (CTRCD). Non-invasive left ventricular (LV) pressure-strain loop (PSL) provides a novel method of quantifying myocardial work (MW) with potential advantages to evaluate the impact of cardiotoxic treatments on heart function. We prospectively assessed breast cancer female patients undergoing cancer therapy through serial monitoring by 2D and 3D TTE. Patients were evaluated at T0, T1 and T2 (before, 4-6 and 12-14 months after starting therapy, respectively). Through PSL analysis, MW indices were calculated. A total of 122 patients, with a mean age of 54.7 years, who received treatment with anthracyclines (77.0%) and anti-HER2 (75.4%) were included. During a mean follow-up of 14.9 ± 9.3 months, LVEF and GLS were significantly diminished, and 29.5% developed CTRCD. All MW indices were significantly reduced at T1 compared with baseline and tended to return to baseline values at T2. Global work index and global work efficiency showed a more pronounced variation in patients with CTRCD. The presence of more than one cardiovascular risk factor, obesity and baseline left atrium volume were predictors of changes in MW parameters. In conclusion, breast cancer treatment was associated with LV systolic dysfunction as assessed by MW, with its peak at 4-6 months and a partial recovery afterwards. Assessment of myocardial deformation parameters allows a more detailed characterization of cardiac remodelling and could enhance patient screening and selection for cardioprotective therapeutics.